FDA Expedited Programs Guidance: “Available Therapies” Depends On U.S. Standard Of Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance explains the four expedited drug development and approval pathways and offers the agency’s first formal advice on the type and amount of evidence needed for designation as a “breakthrough therapy” under FDASIA.